Dr. Figeys, co-founder of MedBiome, becomes the CEO and Director of the Quadram Institute UK
MedBiome congratulates Dr. Daniel Figeys for becoming the new CEO and Director of the Quadram Institute, UK.
MedBiome: finalists at Food Tech Congress 2023
MedBiome is pleased to announced that it a finalists at the Food Tech Congress 2023 startup pitch competition!
MedBiome will be at Bio Europe 2022
MedBiome is pleased to announce that it is attending Bio Europe 2022 on October 24-26 2022. Looking forward to new partnerships.
MedBiome is at BioPharm America Digital
MedBiome is pleased to announce that it is attending the digital BioPharm America Digital on Sept 21-24 2020. Looking forward to new partnerships.
MetaLab 2.0: Bioinformatics for metaproteomics.
Medbiome’s founder recently released a new version of the metaproteomic software called MetaLab 2.0, opening the door to accurate Post-Translational Modifications profiling at the microbiome level. https://pubs.acs.org/doi/10.1021/jasms.0c00083
https://pubs.acs.org/doi/10.1021/jasms.0c00083
MedBiome will be at ChinaBio Partnering Forum Aug 25-27 2020
MedBiome is pleased to announce that it will attend the digital China Bio Partnering Forum on Aug 25-27 2020. Looking forward to new partnerships with Chinese companies.
Medbiome’s founders demonstrated that structurally similar compounds can have distinct effects on individual microbiomes
In a recent paper in Gut Microbes the founders of MedBiome reported the effects of berberine (BBR) and 16 structural analogs on seven individual gut microbiomes using our RapidAIM technology. This article clearly illustrates that the RapidAIM technology can distinguish the effects of structurally similar compounds on individual microbiomes. This is an important milestone when selecting and optimizing compounds to target the gut microbiome.
Testing of a drug panel for effects on the gut microbiome using RapidAIM
MedBiome’s founders reported in Microbiome the development of the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes using the RapidAIM technology. The RapidAIM workflow provides insights into microbiome absolute abundance and functional responses to drugs.
MedBiome licenses the MetaLab metaproteomic software
MedBiome is pleased to announce that it has licensed the iMetaLab software platform from the University of Ottawa. iMetaLab (imetalab.ca) is a leading bioinformatics software for metaproteomics data analysis. MedBiome uses the iMetaLab software in combination with the RapidAIM assay to identify Precision Microbiome Therapeutics that change the composition of the human microbiome, promote the productions of specific metabolites by the human microbiome and for the stratification of patients based on their microbiome responses. MedBiome develops Precision Microbiome Therapeutics for Inflammatory Bowel Disease, Alzheimer’s Disease, Chronic kidney disease and Colorectal cancer.
MedBiome licenses the RapidAIM technology from the University of Ottawa.
MedBiome is pleased to announce that it has exclusively licensed the RapidAIM technology from the University of Ottawa. RapidAIM is a revolutionary assay to rapidly determine the effects of compounds on individual human living microbiomes. RapidAIM fidelity maintains functional living human microbiomes in 96 well plates and allows the testing of drugs for their effects on the microbiome for up to 5 days. RapidAIM is used to identify compounds that change the composition of the human microbiome, promote the productions of specific metabolites by the human microbiome and for the stratification of patients based on their microbiome responses. MedBiome is using the RapidAIM technology to identify microbiome metabolic modulators that promote the production of specific metabolites in Inflammatory Bowel Disease, Alzheimer’s Disease, Chronic kidney disease and Colorectal cancer. MedBiome also provides access to RapidAIM through partnerships.
